This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Today, we’re speaking to Simone Steiner, Transgene’s new chief technology officer, about how the company is transitioning from early- to late-stage testing and advancing its manufacturing capabilities Oncology vaccines are gaining traction in the clinic as potential game changing treatments for cancer.
s CDC Vaccine Committee Overhaul for the Pharmaceutical Industry June 10, 2025 By Christopher Cole News Article The dismissal of all 17 members of the Advisory Committee on Immunization Practices has far-reaching impacts for the industry and beyond. Kennedy Jr. Industry groups have also raised serious concerns. BIO President and CEO John F.
June 13, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook GSK’s vaccine leverages GMMA technology. GSK has licensed altSonflex1-2-3, its Shigella vaccine candidate, to Bharat Biotech for continued development and distribution in low and middle-income nations. Credit: viewimage/Shutterstock.
Fournier, BSc Key Takeaways The 2024-2025 influenza season saw unprecedented severity, with high hospitalization and outpatient visit rates due to a vaccine mismatch and dominant H1N1 and H3N2 strains. Targeted public health strategies are needed to improve vaccine access, education, and trust, particularly in underserved communities.
Expanding use of the 15-valent pneumococcal conjugate vaccine (PCV15) or 20-valent pneumococcal conjugate vaccine (PCV20) to all United States adults aged 50 to 64 years would result in modest budget increases over a 3-year period. 1,2 A particular disease burden is present for Black Americans.
How will RFK Jr’s American dream for vaccines play out? Robert Barrie July 14, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Broader label coverages for Pfizer and Moderna’s vaccines mean they have made in-roads into GSK’s RSV dominant market share. MAXSHOT.PL via Shutterstock.
The Department of Health – Abu Dhabi (DoH) and Sanofi have signed a memorandum of understanding (MoU) to bolster vaccine development by leveraging local health-tech ecosystems and research infrastructure. Credit: Department of Health Abu Dhabi.
14,15 Lung Cancer Tarlatamab Significantly Improves Survival in Patients With Small Cell Lung Cancer Post Progression Tarlatamab has shown promising efficacy in relapsed SCLC based on the initial single-arm trial findings, leading to an FDA approval in 2024, but challenges with administration have limited its widespread adoption.
Related Videos Related Content Advertisement July 21st 2025 Under the Weather: Unpacking the Impact of the 2024-2025 Influenza Season Tori L. Bridging Gaps in Pharmacy Access Newsletter Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights. Subscribe Now!
By 2024, more than 750 Indian facilities were registered with the U.S. Indian pharmaceutical companies supply more than 60 per cent of global demand for vaccines and over 40 per cent of generic medicines consumed in the United States (2). In FY 2024–25, India’s pharmaceutical exports exceeded USD 30.3 Source: IBEF, 2024 3.
5 Phase 3 ECHO Trial: A New Frontline Option The approval was supported by data from the phase 3 ECHO trial (NCT02972840), presented at the 2024 European Hematology Association Hybrid Congress. June 21, 2024. Deaths were reported in 5 TN and 6 R/R patients. The trial enrolled 598 patients 65 years or older with TN MCL. Hemasphere.
Viral hepatitis poses a significant risk to HIV patients, with overlapping transmission modes complicating diagnosis and treatment, highlighting the need for targeted support and vaccination. This is why, according to Nunes, vaccination is critical, especially providing it to nonimmune, non-HBV patients with HIV to prevent infection.
Updated April 2, 2024. A study of JNJ-68284528, a chimeric antigen receptor T cell (CAR-T) therapy directed against B-cell maturation antigen (BCMA) in participants with relapsed or refractory multiple myeloma (CARTITUDE-1). Accessed June 24, 2025.
The FDA approved nemolizumab in December 2024 for the treatment of moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not controlled by topical prescription therapies among individuals 12 and older. May 15, 2024. December 16, 2024. June 6, 2025.
CE hours from BCOP Updates 2024 and the Annual Conference 2025, featuring topics such as acute leukemia, cellular therapy for solid tumors, and the pharmacist’s role in serious illness conversations. HOPA has selected 4.0 Additional information is available here.
Updated November 14, 2024. Updated October 31, 2024. Lastly, pharmacists should consider offering mail-back envelopes at no charge to provide patients with a convenient and secure alternative to other disposal options. REFERENCES 1. The impact of pharmaceuticals released to the environment. Accessed June 6, 2025. 2020;6(7):e04551.
2024 Global Strategy for Asthma Mnagement and Prevention Guidelines. A comprehensive evaluation of asthma therapy within a large healthcare system. Presented at: American Society of Health-System Pharmacists 2025 Pharmacy Futures. Charlotte, NC; June 9, 2025. Global Initiative for Asthma. Accessed June 9, 2025.
Since launching the service in September 2024, they’ve dispensed more than 300 boxes, with an estimated 72% acceptance rate. When patients are prescribed an opioid for the first time, the system alerts staff for a clinical consult. 1 This service can not only expand pharmacies’ clinical offerings but serves a crucial public health benefit.
Updated September 10, 2024. TOC services are one of many areas where pharmacy models can improve patient outcomes, quality metrics, and hospital revenue. 4-6 Since this study’s completion, the institution has expanded its protocol with additional prescribing opportunities for TOC pharmacists and plans to expand services to non-HRRP patients.
2024 ESC guidelines for the management of elevated blood pressure and hypertension. J Am Coll Cardiol. 2018;71:e127-e248. doi:10.1016/j.jacc.2017.11.006 2017.11.006 Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018; 39: 3021–3104. Eur Heart J. JAMA doi:10.1001/jama.2025.6681
This phase 1b clinical trial, conducted between September 2023 and November 2024, was designed to build on promising preclinical data that demonstrated improved efficacy and tolerability with continuous SC lenalidomide delivery in murine MM models.
September 11, 2024. Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study. News release. Accessed June 18, 2025.
A recent study reveals that a single dose of Bavarian Nordics Jynneos vaccine demonstrated 58 per cent overall effectiveness in preventing mpox infection. A clade I outbreak has been ongoing in Central and Eastern Africa since 2024 and has been responsible for over 21,000 infections to date.
1 The current post hoc secondary analysis was conducted from March to June 2024 and aimed to further evaluate the spillover of an audit-and-feedback intervention that targets individuals aged 65 and older on a broader population of all age groups.
FDA approvals dropped in May to 14 drugs after hitting 20 and above in the two months prior, but the total of 84 OKs so far in 2025 is the second only to 2024’s record high for the first part of the year, according to Clarivate. A long-time leader in vaccines, the U.K.
per cent expansion compared to May 2024-25. Vaccines were the third largest exported category, valued at $ 190.13 India’s pharmaceutical export industry continued its growth trajectory in May 2025, reaching $ 4,961.71 This represents a 7.38 per cent during this period. per cent during this period. per cent increase. million.
Last Updated November 11, 2024. Risk Evaluation and Mitigation Strategies | REMS. Last Updated May 20, 2025. Accessed June 30, 2025. American Cancer Society. CAR T-cell therapy and its side effects. Accessed June 30, 2025.
October 19, 2024. December 2024. Efficacy and safety of a novel low-dose triple single-pill combination of telmisartan, amlodipine and indapamide, compared with dual combinations for treatment of hypertension: a randomised, double-blind, active-controlled, international clinical trial. The Lancet. doi: 10.1016/S0140-6736(24)01744-6 5.
Records from patients who received oncology treatment from Walgreens Specialty Pharmacy from December 2023 to October 2024 were analyzed to determine the percentage of patients who opted for a fertility preservation counseling session. Materials and Methods This study design was descriptive, nonexperimental, and retrospective.
Updated June 20, 2024. 2024 US Generic & Biosimilar Medicines Savings Report. September 2024. This direct engagement is crucial in building confidence in biosimilars and ensuring their appropriate utilization, contributing to more affordable and accessible health care. REFERENCES 1. Accessed May 13, 2025. JAMA Health Forum.
This single-center, retrospective, observational study included data from electronic health records and specialty pharmacies from January 1, 2023, to June 1, 2024, with specialty pharmacy dispensing data specifically used to identify patients who had received Humira and a biosimilar during the study period. Subscribe Now!
Published June 6, 2024. As CBD’s popularity surges, ensuring hepatic safety becomes a core component of patient care. REFERENCES Minnerd J. Even Low Doses of CBD May Elevate Liver Enzymes in Healthy Adults. MedPage Today. link] ClinicalTrials.gov. Published April 10, 2024. link] Tallon MJ, Child R.
CE hours from BCOP Updates 2024 and the Annual Conference 2025, featuring topics such as acute leukemia, cellular therapy for solid tumors, and the pharmacist’s role in serious illness conversations. HOPA has selected 4.0 Additional information is available here.
September 11, 2024. Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study. News release. Accessed June 18, 2025.
December 3, 2024. months progression-free survival in real-world RRMM patients, consistent with KarMMa trial results. July 10, 2025. Doi:10.1182/blood.2024026216 2024026216 3. Study shows comparable safety, efficacy of idecabtagene vicleucel in older patients. Pharmacy Times. Accessed July 15, 2025. July 10, 2025. Doi:10.1182/blood.2025029274
3 This recommendation is in contrast to the 2024 Society of Critical Care Medicine (SCCM) Guidelines on Use of Corticosteroids in Sepsis, Acute Respiratory Distress System, and Community-Acquired Pneumonia, which recommend the use of corticosteroids in patients with severe CAP. Intensive Care Med. 2021;47(11):1181-1247. Crit Care Med.
The field is expanding into autoimmune diseases, with nononcology trials representing 51% of the pipeline by late 2024. Development Trends: Oncology at the Forefront Gene therapy currently ranks third among therapeutic focus areas, with 2151 compounds in development in 2024 ( Figure ).
August 8, 2024. Updated January 19, 2024. LinkedIn Workplace Learning Report 2024. American Oncology Network. Accessed May 15, 2025. How your oncology peers manage the complexities of care. Oncology Live ®. December 13, 2018. Accessed May 15, 2025. Desimone R. Improve work performance with a focus on employee development.
All these challenges tend to lead to high costs for therapeutics and vaccines leveraging nanoscale drug delivery systems. The improved targeting capability of nanoscale delivery systems also leads to improved activation of immune cells in cancer vaccines. Anti-Cancer Drugs. DOI: 10.3389/fphar.2024.1389922. 2024.1389922. link] fimmu.2024.1427573
Updated November 13, 2024. link] eptinezumab-jjmr -the-first-a New data demonstrates robust efficacy of Eptinezumab-jjmr® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine. News release. PR Newswire. June 21, 2025. Accessed July 2, 2025. link] Aetna. Clinical Policy Bulletin 0970: Eptinezumab‑jjmr (Eptinezumab-jjmr).
Gates said the idea for the program came from the Walgreens Deans Advisory Council, which Walgreens launched in 2024. Furthermore, 24.9% 2 Helping potential students navigate these challenges could encourage pharmacy school applications and benefit those who apply.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content